Carl Goodman, MD
Orthopedic Surgery · Shreveport, LANPI 1346244290
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $170, more than ten times the $11 reported in 2019.
Across 19 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$58
- Innovation Technologies Inc$41
- Nalu Medical, Inc.$39
- Solventum Corporation$37
- Pacira Pharmaceuticals Incorporated$35
- Abbott$34
- plus $158 from 8 others
What the payments were for
- Food & beverage$37694%
- Other$256%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 3 | $58 |
| Innovation Technologies Inc | 2 | $41 |
| Nalu Medical, Inc. | 1 | $39 |
| Solventum Corporation | 1 | $37 |
| Pacira Pharmaceuticals Incorporated | 2 | $35 |
| Abbott | 2 | $34 |
| Davol Inc. | 1 | $31 |
| Welch Allyn | 1 | $25 |
| Vericel Corporation | 1 | $24 |
| Boston Scientific | 1 | $19 |
| Amgen | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Fidia Pharma USA Inc. | 1 | $14 |
| Bioventus LLC | 1 | $14 |
How this compares
Too few orthopedic surgery providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 13 | $4,119 |
| Tramadol Hcl | 143 | $1,024 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $305 |
| Gabapentin | 24 | $232 |
| Cyclobenzaprine Hcl | 25 | $137 |
| Meloxicam | 13 | $44 |
| Alprazolam | 13 | $24 |
Paid to pharmacies, not to this prescriber.
Other orthopedic surgery in Shreveport
- Edward YergerLafayette$39K
- Luis EspinozaKenner$11K
- Joseph BoucreeSlidell$7K
- Michael HollandJennings$4K
- Robert NicholsonHammond$1K
- Thomas LyonsKenner$1K
- Paul van DeventerMandeville$1K
- John SchutteLafayette$35
- Douglas BernardNew Iberia$0
- Ronald SylvestBaton Rouge$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.